StocksMedium•12 November 2026•
1 min read
Pelthos Therapeutics Revenue Surges 114% on Strong Zelsuvmi Sales in Q3
Key Facts
1Pelthos Therapeutics reported a 114% growth in Zelsuvmi net product revenue to $15.2 million during Q3 2026.
Pelthos Therapeutics reported a 114% growth in Zelsuvmi net product revenue to $15.2 million during the third quarter of 2026. GlobeNewswire reported that 12,384 Zelsuvmi units were dispensed by 4,942 unique prescribers during the quarter, representing a 4% increase in units dispensed compared to the previous quarter.
Pelthos Therapeutics, trading under the ticker PTHS, closed at $9.39 on November 11, 2026. The stock reached a high of $9.61 and a low of $8.72 on November 11, 2026, as the company maintains commercial momentum and prepares for the planned launches of Xepi and Xeglyze in 2027.